Merus and Halozyme partner on subcutaneous petosemtamab formulation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Dow leads Wall Street higher, investors focus on healthcare stocks
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 124.37 +1.87 (1.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $122.50 | 52 Week High | $18.39 | |||
| Open | $123.54 | 52 Week Low | $6.96 | |||
| Day High | $125.10 | P/E | N/A | |||
| Day Low | $123.00 | EPS | $-0.58 | |||
| Volume | 2,202,243 | |||||
| (NASDAQ: MRUS) | Delayed: 90.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.00 | 52 Week High | $19.63 | |||
| Open | $90.00 | 52 Week Low | $7.26 | |||
| Day High | $90.00 | P/E | N/A | |||
| Day Low | $90.00 | EPS | $0.00 | |||
| Volume | 642,799 | |||||
